The most common type of non-Hodgkin's lymphoma is called diffuse large B-cell lymphoma (DLBCL). One in three people with lymphoma have this type, and it mainly affects older adults. It’s a fast ...

Roche (RHHBY) announced that the European Commission, EC, has approved Columvi in combination with gemcitabine and oxaliplatin for the ...

Roche’s bispecific antibody, Columvi receives European approval for diffuse large B-cell lymphoma after initial therapy: Basel Tuesday, April 15, 2025, 10:00 Hrs [IST] Roche ann ...

Roche’s Columvi (glofitamab) has been approved by the European Commission (EC) as part of a combination treatment for diffuse ...

The following is a summary of “Identification of molecular clusters and a risk prognosis model for diffuse large B-cell ...

Innovative polatuzumab vedotin plus R-CHP therapy reshapes treatment of older adult patients with diffuse large B-cell lymphoma.

is being investigated in relapsed/refractory large B-cell lymphoma. The investigational allogeneic chimeric antigen receptor (CAR) T-cell therapy cemacabtagene ansegedleucel (cema-cel; Allogene ...

Approval based on Phase III STARGLO study where Columvi in combination with chemotherapy showed a 41% reduction in the risk ...

Basel: Roche has announced that the company has received approval from the European Commission for Columvi (glofitamab) in ...